Top Markets
#1 Black Phoenix Black Phoenix +167.57%
#2 Islamic Coin Islamic Coin +158.27%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +33.17%
#5 Test Test +21.48%
#6 Cryptopia Cryptopia +20.92%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.26%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +16.56%
#9 stake.link stake.link +9.38%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.37%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ReNeuron Group plc ReNeuron Group plc

ReNeuron Group plc

RENE
Kedudukan dalam Saham #41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Harga Saham
$0.00042815
Disegerakkan terakhir: 2024-02-27
Modal Pasaran
$13.55K
Perubahan (1 hari)
0.03%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan ReNeuron Group plc (RENE)

Kategori

Healthcare
Nisbah P/E bagi ReNeuron Group plc (RENE)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini ReNeuron Group plc, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi ReNeuron Group plc dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.